Mersana Therapeutics, Inc. — Net Income by Fiscal Year
10 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/1c0f46b6-f5c5-4dfa-93b8-ad209764f179/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2024 | $-69.2M | 2024-01-01 – 2024-12-31 | evidence 0001628280-25-009246 |
| FY 2023 | $-171.7M | 2023-01-01 – 2023-12-31 | evidence 0001628280-24-007407 |
| FY 2022 | $-204.2M | 2022-01-01 – 2022-12-31 | evidence 0001628280-23-005376 |
| FY 2021 | $-170.1M | 2021-01-01 – 2021-12-31 | evidence 0001628280-22-004101 |
| FY 2020 | $-88.0M | 2020-01-01 – 2020-12-31 | evidence 0001628280-21-003370 |
| FY 2019 | $-28.2M | 2019-01-01 – 2019-12-31 | evidence 0001558370-20-001726 |
| FY 2018 | $-64.3M | 2018-01-01 – 2018-12-31 | evidence 0001558370-19-001720 |
| FY 2017 | $-38.7M | 2017-01-01 – 2017-12-31 | evidence 0001558370-18-002479 |
| FY 2016 | $-13.7M | 2016-01-01 – 2016-12-31 | evidence 0001558370-17-006537 |
| FY 2015 | $-16.4M | 2015-01-01 – 2015-12-31 | evidence 0001558370-18-002479 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).